| 764018 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
670 Oxidative stress originating in the mitochondria damages telomeres sufficient to drive certain features of T cell dysfunction |
2021-11-01 |
10.1136/jitc-2021-sitc2021.670 |
Rivadeneira Dayana, Yana Jess, Thosar Sanjana, Bruchez Marcel, Lynn Patricia, Delgoffe Greg |
| 764017 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
669 Lactate uptake through MCT11, a novel monocarboxylate transporter, enforces dysfunction in terminally exhausted T cells |
2021-11-01 |
10.1136/jitc-2021-sitc2021.669 |
Peralta Ronal, Delgoffe Greg |
| 764016 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
668 Lipid-instructed metabolic rewiring unleash the anti-tumor potential of CD8+ T cells |
2021-11-01 |
10.1136/jitc-2021-sitc2021.668 |
Manzo Teresa, Lauveson Carina Nava, Frasconi Teresa Maria, Tiberti Silvia, Caruana Ignazio, Nezi Luigi, Greenberg Philip |
| 764015 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
667 Tumor-derived alpha-fetoprotein requires polyunsaturated fatty acids for immuno-metabolic dysregulation |
2021-11-01 |
10.1136/jitc-2021-sitc2021.667 |
Munson Paul, Adamik Juraj, Butterfield Lisa |
| 764014 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.506 |
Middleton Mark, Milhem Mohammed, Aroldi Francesca, Sacco Joseph, VanderWalde Ari, Baum Scott, Samson Adel, Chesney Jason, Niu Jiaxin, Rhodes Terence, Bowles Tawnya, Emamekhoo Hamid, Tsai Katy, In Gino, Beasley Georgia, Chmielowski Bartosz, Dalac-Rat Sophie, Kahler Katharina, Muñoz Eva, Olsson-Brown Anna, Bommareddy Praveen, Menezes Lavita, Pirzkall Andrea, Coffin Robert, Harrington Kevin |
| 764013 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
505 Relationship of infusion duration and dose to safety, efficacy and pharmacodynamics: second part of a phase 1–2 study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.505 |
Patel Manish, Powell Steven, Strauss James, Johnson Melissa, Cripe Timothy, Peng Kah-Whye, Russell Stephen, Russell Luke, Reckner Monica, Wiegert Erol, Bexon Alice, Merchan Jaime |
| 764012 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
504 A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.504 |
Melero Ignacio, Calvo Emiliano, Goebeler Maria-Elisabeth, Garralda Elena, Dummer Reinhard, Rodríguez-Ruiz María, Miguel Maria de, Sayehli Cyrus Michael, Casal Guzman Alonso, Ramelyte Egle, Schuler Martin, Gromke Tanja, Sanmamed Miguel, Moreno Irene, Bargou Ralf, Lostes Maria, Maul Julia-Tatjana, Eggenschwiler Corinne, Richly Heike, Fettes Petra, Klar Kathrin, Schuberth-Wagner Christine, Haake Markus, Wischhusen Jörg, Leo Eugen |
| 764011 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
503 Clinical activity of ICT01, an anti-BTN3A-targeted, γ9δ2-activating mAb, alone and in combination with pembrolizumab in patients with advanced/refractory solid tumors: EVICTION trial |
2021-11-01 |
10.1136/jitc-2021-sitc2021.503 |
Wermke Martin, Marabelle Aurelien, Jungels Christiane, Bono Johann De, Vey Norbert, Vicier Cécile, Garralda Elena, Gouill Steven Le, LoRusso Patricia, Champiat Stephane, List Catrin, Aguiar Vladimir Galvaö de, Wetzko Katrin, Rhunke Leo, Gassart Aude de, Brune Patrick, Valentin Emmanuel, Iche Marina, Olive Daniel, Frohna Paul |
| 764010 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
502 Recommended phase 2 dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the IL-15 superagonist SO-C101 as monotherapy in patients with advanced/metastatic solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.502 |
Marabelle Aurelien, Champiat Stéphane, Galvao Vladimir, Naing Aung, Janku Filip, LoRusso Patricia, Grell Peter, Sachse Richard, Bechard David, Kiemle-Kallee Joachim, Garralda Ellena |
| 764009 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
501 Survival and immune response data from intratumoral INT230–6 alone (IT-01) and with pembrolizumab [KEYNOTE-A10] in subjects with locally advanced, unresectable and metastatic solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.501 |
Thomas Jacob, El-Khoueiry Anthony, Olszanski Anthony, Azad Nilofer, Whalen Giles, Hanna Diana, Ingham Matthew, Mahmood Syed, Bender Lewis, Walters Ian, Siu Lilian |
